H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to invest in. On May 21, H.C. Wainwright boosted Immunovant, Inc.
Immunovant Inc. (IMVT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 11,526,971 | $286,329,960 | 4.68% | |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,457,881 | $135,573,764 | 0.78% | |
| 3. | Armistice Capital Steven Boyd | 3,564,916 | $88,552,513 | -38% | 1.57% |
| 4. | Two Seas Capital Sina Toussi | 3,201,962 | $79,536,736 | +12% | 1.11% |
| 5. | ADAR1 Capital Management Daniel Schneeberger | 2,679,010 | $66,546,608 | +8% | 3.92% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.00 | 16,666,666 | $349,999,986.00 | 113,317,007 | 2025-12-12 | Filing | |
| $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | 2025-01-13 | Filing | |
| $38.00 | 1,526,316 | $58,000,008.00 | 79,805,331 | 2023-10-02 | Filing | |
| $6.00 | 416,667 | $2,500,002.00 | 73,805,331 | 2022-10-06 | Filing | |
| $5.60 | 15,000 | $84,000.00 | 20,000 | 2022-09-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.99 | 106 | $4,238.94 | 222,357 | 2026-07-08 | Filing | |
| $39.53 | 1,930 | $76,292.90 | 222,463 | 2026-07-08 | Filing | |
| $39.99 | 63 | $2,519.37 | 179,391 | 2026-07-08 | Filing | |
| $39.53 | 1,143 | $45,182.79 | 179,454 | 2026-07-08 | Filing | |
| $39.99 | 77 | $3,079.23 | 208,198 | 2026-07-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 120,686 | $4,650,032 | 0.13% | |
| 2. | 16,577 | $638,712 | 0% | |
| 3. | 13,000 | $500,890 | 0.27% | |
| 4. | 748 | $28,820 | 0% | |
| 5. | 184 | $7,090 | 0% |
News See All
13 Best Short Squeeze Stocks to Invest In
US markets climbed to record highs, wrapping up a solid month, as President Trump announced he will soon make a decision on the Iran deal.
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
Immunovant, Inc. (NASDAQ:IMVT) is one of the best momentum stocks to buy according to analysts. Truist lifted the price target on Immunovant, Inc.
10 Best Momentum Stocks to Buy According to Analysts
On May 22, Steve Sosnick, from Interactive Brokers, appeared on CNBC’s ‘Power Lunch’ to talk about what is driving the record market moves.
Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial
Immunovant saw its share prices soar to a new five-year high on Wednesday, as investors took heart from the stellar results of its clinical trial to study its drug candidate for hard-to-treat rheumatoid...
10 Stocks With Insane Returns Right Now
POET Technologies snapped a three-day losing streak on Wednesday, climbing 13.08 percent to close at $14.78 apiece, after announcing an aggressive plan to expand its wafer manufacturing capabilities by...
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update
Immunovant, Inc. (NASDAQ:IMVT) ranks among the most shorted stocks to buy according to analysts. On February 6, Immunovant, Inc.
11 Most Shorted Stocks to Buy According to Analysts
Although holes are starting to form, the stock market doesn't seem to be in danger of crashing just yet, with the S&P 500 down only 1% from its record high.
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Roivant Third Quarter 2025 Earnings Conference Call.
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling
Immunovant Inc. (NASDAQ:IMVT) is one of the promising stocks to buy under $50.